Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells 55,000 Shares of Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of the business’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $15.93, for a total value of $876,150.00. Following the completion of the sale, the chief executive officer now owns 331,017 shares in the company, valued at approximately $5,273,100.81. The trade was a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Saurabh Saha also recently made the following trade(s):

• On Tuesday, January 21st, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.77, for a total value of $867,350.00.
• On Friday, December 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $17.44, for a total transaction of $959,200.00.
• On Friday, December 6th, Saurabh Saha sold 87,496 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $18.46, for a total transaction of $1,615,176.16.
• On Monday, November 25th, Saurabh Saha sold 299 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.23, for a total transaction of $5,450.77.
• On Friday, November 22nd, Saurabh Saha sold 1,671 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.24, for a total transaction of $30,479.04.

Centessa Pharmaceuticals Trading Down 0.7 %

Shares of CNTA opened at $16.63 on Friday. Centessa Pharmaceuticals plc has a 1-year low of $7.75 and a 1-year high of $19.09. The company has a market capitalization of $2.19 billion, a P/E ratio of -10.87 and a beta of 1.53. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The firm’s 50 day simple moving average is $16.71 and its 200 day simple moving average is $15.87.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. TD Cowen began coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating on the stock. Guggenheim reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Monday, February 10th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $25.83.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of institutional investors have recently made changes to their positions in CNTA. Janus Henderson Group PLC raised its position in shares of Centessa Pharmaceuticals by 279.2% during the 4th quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company’s stock valued at $82,218,000 after buying an additional 3,614,623 shares in the last quarter. Foresite Capital Management VI LLC purchased a new stake in shares of Centessa Pharmaceuticals during the 4th quarter valued at $20,994,000. Franklin Resources Inc. raised its holdings in shares of Centessa Pharmaceuticals by 99.1% during the 3rd quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock valued at $38,360,000 after buying an additional 1,145,823 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in shares of Centessa Pharmaceuticals by 54.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company’s stock valued at $43,423,000 after buying an additional 953,659 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. lifted its position in Centessa Pharmaceuticals by 22.0% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company’s stock worth $85,744,000 after buying an additional 924,027 shares during the last quarter. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.